A detailed history of Octagon Capital Advisors LP transactions in Allovir, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 11,202,000 shares of ALVR stock, worth $6.16 Million. This represents 2.19% of its overall portfolio holdings.

Number of Shares
11,202,000
Previous 9,800,000 14.31%
Holding current value
$6.16 Million
Previous $7.06 Million 28.59%
% of portfolio
2.19%
Previous 1.63%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.7 - $0.82 $981,399 - $1.15 Million
1,402,000 Added 14.31%
11,202,000 $9.07 Million
Q2 2024

Aug 14, 2024

BUY
$0.72 - $0.82 $4.03 Million - $4.59 Million
5,600,000 Added 133.33%
9,800,000 $7.06 Million
Q1 2024

May 15, 2024

BUY
$0.64 - $0.78 $2.69 Million - $3.28 Million
4,200,000 New
4,200,000 $3.19 Million

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $51.2M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.